Supplements

AHA, AAP, ACOG, and SMFM issued a Female Life Stage framework that starts cardiovascular risk assessment at perimenarche, around ages 8 to 15.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.

A four-dose 25-valent PCV series elicited responses to all 25 serotypes in infants, with serotype 3 GMCs ~15-fold higher than PCV20 after dose 4.

Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.

Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.

Adding emotion skills to family-based weight treatment didn't boost teen weight loss but cut regain and emotional eating 12 months later.